Kalbe Farma KLBF IJ -Buy- Transforming the brand
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Consumer Durables SH JW SC 511 14th Oct, 2024
Maintain Buy with a higher TP of IDR4,300; roll forward base year to FY25F
Margin likely bottoming out in 3Q24F; only a temporary phase
We believe Mayora’s 3Q24F GPM will likely be lower than market expectation due to the full impact of higher coffee and cocoa costs in 3Q, as the company started buying new inventory in 2Q24, as well as higher fixed costs from the operation of its new factory in East Java in Sep-24. We expect a lower A&P-to-sales ratio in 3Q24F but this, in our view, would not be enough to offset the rise in raw material costs. That said, we assume that 3Q24F margin should bottom out with a likely recovery in 4Q24F, as the company will absorb the stronger price hike impact and lower USD-related costs, while coffee price contracts have been locked in until 2Q25. We also believe the new factory can ramp up utilization quickly to meet wafer demand, offsetting higher fixed costs. Moreover, MYOR could accelerate price hikes in 4Q24F, given a strong consumption backdrop amid election of local leaders, in our view. We are not concerned about margins, as historically MYOR has gradually passed on costs, and whenever raw material prices normalize, it has enjoyed strong margin recovery. Mayora's GPM declined in 2022, quickly recovering from 22.3% to 26.7% in 2023.
Most important metric is sales: strong consumption plus market share gain
We believe MYOR could record mid-high-teens sales growth in 3Q24F, higher than Bloomberg consensus estimates. We would expect this to be equally driven by both domestic and export sales volume, while ASP may only contribute 1-2% YTD We think a jump in coffee and cocoa prices could be a blessing in disguise for MYOR as its competitors may suffer more severely, allowing the company to gain market share rapidly. Notably, MYOR has expanded its market share in the instant coffee market in the Philippines from ~40% last year to 50% level in 2024. Domestic market also enjoys strong organic consumption, with even stronger sales in Sep-24, nearing the local leaders’ levels during Nov-24 election period. We also expect another sales surprise in 4Q24F.
Still undervalued; rolling forward our TP to IDR4,300, implying 63% upside
We raise our sales forecasts by 6%/8% for FY24F/FY25F, while adjusting EPS by -12%/-3% to factor in higher input costs. We believe there could be a knee-jerk reaction post-3Q24F results release due to subpar margins and forex loss. Next year, we expect consumer companies such as MYOR will benefit from potential Prabowo regime consumption-push programs, i.e., free nutritious food, cash transfer, and tax relaxation programs. We roll forward our TP using a FY25F P/E of 26.5x (unchanged; equivalent to +0.2SD of its 5-year-mean), resulting in a higher TP of IDR4,300. We maintain our Buy call. The stock currently trades at what we view as an undemanding FY25F P/E valuation of 16.3x.
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
Rating Remains | Buy |
Target price Increased from IDR 3,800 | IDR 4,300 |
Closing price 11 October 2024 | IDR 2,640 |
Implied upside | +62.9% |
Market Cap (USD mn) | 3,789.9 |
ADT (USD mn) | 1.6 |
M cap (USDmn) | 3,789.9 |
Free float (%) | 15.7 |
3-mth ADT (USDmn) | 1.6 |
(%) | 1M | 3M | 12M |
Absolute (IDR) | -2.2 | 7.8 | 0.0 |
Absolute (USD) | -3.4 | 12.0 | 0.7 |
Rel to Jakarta Stock Exchange Composite Index | 0.9 | 4.7 | -8.5 |
Sandy Ham (sandy.ham@verdhana.id)
Jody Wijaya (jody.wijaya@verdhana.id)
Samuel Christian (samuel.christian@verdhana.id)